Date: 2014-04-25
Type of information: Services contract
Compound: drug discovery services
Company: LEO Pharma (Denmark) Fidelta (Croatia - a Galapagos company Belgium)
Therapeutic area: Dermatological diseases
Type agreement: R&D services
Action mechanism:
Disease: Dermatological diseases
Details: * On April 25, 2014, Fidelta, a Galapagos company, has announced that it has signed an integrated drug discovery collaboration agreement with LEO Pharma. Under the terms of the agreement, Fidelta will apply its extensive drug discovery expertise to an undisclosed target within LEO Pharma’s dermatology drug discovery portfolio.
Fidelta, a subsidiary of Galapagos NV, is a fee-for-service, collaborative drug discovery organization that combines expertise in the areas of chemistry, pharmacology, ADME, pharmacokinetics and toxicology. Fidelta offers fully integrated services, as well as flexible stand-alone solutions for projects in discovery and early pre-clinical development.
Financial terms:
Latest news:
